Patients with human immunodeficiency virus (HIV) infection are at increased risk of developing coronary heart disease (CHD). Although factors potentially contributing to this elevated risk include traditional CHD risk factors and antiretroviral medications, more recent data support a role for inflammatory and immunologic factors as central to a complex mechanism. Decreasing CHD risk among HIV-infected patients is likely to involve modification of inflammatory and immunologic factors through antiretroviral therapy or other novel strategies as well as targeted treatment of traditional CHD risk factors. This review will highlight epidemiologic data investigating the association between HIV and CHD outcomes. An overview of potential mechanistic factors associated with CHD in HIV infection and of strategies for managing CHD risk in HIV-infected patients is also included. Specific cardiovascular and metabolic risk factors, CHD risk prediction, and the immunologic basis for CHD in HIV-infected patients will be discussed in separate reviews.
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Treatment for human immunodeficiency virus (HIV)
infection has become increasingly accessible and effective in many clinical settings, with reductions in mortality rates attributable to the treatment of infectious complications of advanced HIV disease [1] [2] [3] and increased life expectancy [4, 5] . However, as HIV-related mortality has decreased, there has been a concomitant relative increase in the proportion of deaths attributable to noninfectious complications, including cardiovascular disease (CVD) [3, [6] [7] [8] [9] . Non-AIDS events have specifically been shown to be associated with increased mortality rates relative to AIDS events [10, 11] . Moreover, CVD has been shown to impact morbidity, as demonstrated by a trend in the rise of CVD hospitalization rates [12] . The World Health Organization predicts that HIV/AIDS and ischemic heart disease will be in the top 3 causes for both global mortality and global disability-adjusted life-years in the year 2030, suggesting that an interdependency of these 2 diseases will pose a major global clinical and public health challenge [13] .
CORONARY HEART DISEASE OUTCOMES COMPARING HIV-INFECTED PATIENTS WITH CONTROL PATIENTS
Studies investigating coronary heart disease (CHD) outcomes comparing HIV-infected patients with control patients have consistently shown HIV-infected patients to be at increased risk over time and across varied clinical settings. Coronary heart disease hospitalization rates were significantly higher in HIV-infected patients than in non-HIV-infected patients in an ongoing observational study of the Kaiser Permanente Medical Care Program of Northern California [14] , with recently updated data showing a significantly increased adjusted rate ratio for CHD (rate ratio, 1.2; 95% confidence interval [CI], 1.1-1.4) and for acute myocardial infarction (AMI) (rate ratio, 1.4; 95% CI, 1.3-1.7) [15] . In a study of California Medicaid claims data including .3 million patients, CHD incidence was significantly increased in HIV-infected patients versus non-HIV-infected patients for men aged #34 years and women aged #44 years [16] . Data from the Partners HealthCare System in Boston have also demonstrated increased AMI incidence rates in HIV-infected patients versus non-HIV-infected patients, with a relative risk (RR) for AMI of 1.75 (95% CI, 1.51-2.02) in multivariate modeling adjusting for demographics and common CHD risk factors [17] (Figure 1 ). Comparing rates of first hospitalization for ischemic heart disease in Danish patients infected with HIV versus a population-based control group, HIV-infected patients had a significantly increased risk (adjusted RR, 2.12; 95% CI, 1.62-2.76) [18] . The incidence of AMI was increased in the French Hospital Database on HIV (FHDH) cohort compared with sex-and age-standardized rates from the general French population, with a standardized morbidity ratio of 1.5 (95% CI, 1.3-1.7) [19] and was similarly increased in a Quebec HIV cohort compared with a matched control group, with an adjusted incidence ratio of 2.11 (95% CI, 1.69-2.63) [20] . Finally, recent data from over 28 000 patients in the Veterans Administration (VA) system showed a significantly increased risk of AMI in HIV-infected patients versus non-HIV-infected patients, with an adjusted hazard ratio of 1.94 (95% CI, 1.58-2.37) [21] . Taken together, these data suggest that HIV infection confers a heightened risk of CHD that is independent of demographic characteristics or traditional vascular risk factors.
CHD IN SPECIFIC HIV POPULATIONS

Women
Mortality trends in HIV-infected women parallel those of the general HIV population, with decreasing AIDS-related mortality and increasing CVD-related mortality [22] . Several studies suggest that the impact of HIV infection on CHD is relatively greater for women compared with men. In the Partners cohort, the adjusted RR for AMI comparing HIV-infected patients with non-HIV-infected patients was 3.0 for women versus 1.4 for men [17] . Findings from the FHDH cohort closely paralleled these results, with standardized morbidity ratios for AMI comparing HIV-infected patients with non-HIV-infected patients greater for women (2.7) compared with men (1.4) [19] . Investigation of cardiovascular trends in HIV-infected women, however, is limited by the fact that women are traditionally underrepresented in both HIV clinical trials [23] and in cohort studies of HIV and CVD, with the proportion of female patients in several major studies ranging from 0% to 30% [14, 16, 17, 24, 25] .
Hepatitis C Virus-Coinfected Patients
Whether coinfection with hepatitis C virus (HCV) alters CVD risk for HIV-infected patients is also an area of active investigation. In a study of the Veterans Aging Cohort Study Virtual Cohort, patients coinfected with HIV and HCV had a significantly higher risk of CHD compared with those who were HIVinfected alone or those who had neither infection [26] . Similarly, another study showed rates of CVD to be significantly higher among HIV/HCV coinfected patients versus HIV monoinfected patients in adjusted analyses, with a trend for an increase in AMI rates [27] . However, no association between HCV status and AMI was observed in another large HIV cohort [28] .
POTENTIAL MECHANISTIC FACTORS CONTRIBUTING TO HIV-ASSOCIATED CHD
The mechanism of CHD among HIV-infected patients is likely to reflect a complex interplay of factors, including traditional CHD risk factors, antiretroviral drug effects, and HIV-related parameters, including inflammatory and immunologic changes. A multifactorial etiology is supported by the association of HIV with multiple vascular indices reflecting discrete and progressive stages of atherosclerosis, ranging from endothelial dysfunction [29] [30] [31] to increased carotid intima media thickness (a validated marker of preclinical atherosclerosis) [32] [33] [34] [35] [36] to coronary artery calcification [37, 38] to coronary plaque itself [39] . 
Traditional CHD Risk Factors
Coronary heart disease risk factors established in the general populationdincluding smoking, dyslipidemia, diabetes, hypertension, and visceral adipositydhave been shown to be increased and to confer CHD risk in HIV populations [17, [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] . Metabolic factors associated with HIV infection are described in detail in reviews by Stanley et al and Harris et al (this supplement). Despite a plausible role for traditional CHD risk factors to be important contributors among HIV-infected patients, they are not likely to be solely responsible for elevated CHD risk in this group, as significant levels of risk have been shown to remain after adjustment for traditional CHD risk factors in multivariate analyses [17, 32] . The remaining risk might be explained in part by both antiretroviral medications and novel CHD risk factors including inflammation and immune dysfunction. [24] . In contrast, a large study from the VA system showed no effect between any ART class and CHD or cerebrovascular event outcomes [54] . The conflicting results might be attributable to differing stages of disease in the cohorts, with ongoing viral replication and consequent inflammation possibly obscuring adverse medication effects.
More recent analyses have focused on individual antiretroviral drugs. Following the finding that adjustment for the nucleoside reverse transcriptase inhibitor (NRTI) class of medications attenuated AMI risk in the D:A:D cohort, the group demonstrated recent use of abacavir to be associated with a relative risk of AMI of 1.90, an unanticipated finding given the absence of known metabolic effects [55] . Acute myocardial infarction rates were higher for abacavir users versus nonusers in each predicted CHD risk category, with the highest relative risk of AMI in the lowest predicted risk category (yet, as anticipated, higher absolute rates in the higher predicted risk categories for both abacavir users and nonusers) [55] . Subsequent investigations have shown significant associations of AMI with abacavir, didanosine, lopinavir/ritonavir, and indinavir in a follow-up D:A:D analysis [56] and with lopinavir/ritonavir, amprenavir/ritonavir, and fosamprenavir/ritonavir in an analysis from the FHDH cohort [57] .
Multiple studies examining the potential abacavir-AMI association using alternate data sources have been presented or published since the initial D:A:D finding in 2008, with conflicting results (Table 1) . Although some studies have confirmed the initial finding [20, [58] [59] [60] [61] , others, including 3 studies each 
Persistent CHD Risk in the Setting of Virologic Suppression
Although suppressing viral replication with ART reduces inflammation and immune activation, it does not fully normalize these processes [82, 102] , and data suggest that even residual levels can result in adverse clinical outcomes. A recent study demonstrated a specific association between immune activation markers and carotid artery plaque in patients virologically suppressed on ART, suggesting that persistent immunologic and inflammatory changes remain important in mediating CHD [98] . Further supporting a role for chronic HIV-related effects in CHD risk are data that showed carotid intima media thickness to be elevated in all HIV groups versus controls, including in elite controllers (HIV-infected patients who maintain an undetectable HIV RNA by standard assay in the absence of ART), independent of ART exposure, viremia, or advanced immunodeficiency [33] . Taken together, available data suggest that the mechanism of HIV-related CHD is
indeed complex, with important etiologic factors beyond traditional CHD risk factors and antiretroviral medications. It is likely that the inflammatory and immunologic consequences of a chronic infectious processdeven when controlled on medicationsdunderlie the development of premature atherosclerosis and a clinical scenario of accelerated aging.
STRATEGIES FOR CHD RISK REDUCTION AMONG HIV-INFECTED PATIENTS
Predicting CHD Risk
Commonly used CHD risk prediction tools have been applied but not formally validated for use in HIV-infected populations [103] that may differ from the population for which the rules were derived with respect to demographic composition and the presence of nontraditional risk factors. Coronary heart disease risk estimation for HIV-infected patients is discussed in detail in the review by D'Agostino (this supplement).
Role of HIV Therapy
Recent data have prompted a major shift in thinking about the role of ART in relation to CHD risk. Although it was previously thought that virologic suppression came at the expense of possible proatherogenic side effects of antiretroviral drugs, current data suggest that the overall benefits of treatmentdin terms of virologic suppression with concomitant reduction in inflammatory markers and improvement of immune functiondare likely to be cardioprotective. Furthermore, improved toxicity profiles of first-line antiretroviral agents over time may have led to decreased CHD risk, which has yet to be captured in large cohort studies. In a notable reflection of these changes, the 2010 International AIDS Society-USA treatment guidelines cited high baseline cardiovascular risk as an indication to initiate ART Modulating inflammation and immune activation that persist despite virologic suppression is likely to be an important approach to prevent CHD in HIV-infected patients. Several strategies are being explored, as discussed in depth by Hsue et al (this supplement). In preliminary studies, treatment intensification has been investigated to reduce low-level viral replication thought to be associated with inflammation and immune activation, with varying results [123] [124] [125] . Additionally, statins might have a role beyond lipid lowering in reducing inflammation. Statins have been specifically shown to decrease C-reactive protein in HIV-infected patients on boosted PIs [126] , and a recent study showed overall mortality to be decreased with statin therapy in an HIV cohort, although CHD mortality was not able to be assessed specifically due to the small number of outcome events [127] . Finally, microbial translocation in the gut is postulated to fuel persistent immune activation, and immunomodulatory therapies are being explored to target this process [128] .
FUTURE DIRECTIONS AND IMPLICATIONS
The intersection of HIV infection and CHD poses significant challenges from a clinical standpoint for those providing care to HIV-infected patients and from a public health standpoint in light of the global impact of both diseases. Although recent investigations have enhanced our knowledge of this complex area, important questions remain unanswered: What is the role of HIV treatment and its timing in decreasing CHD risk? Which HIV-infected patients should be prescribed aspirin? Is there a role for statins for HIV-infected patients beyond that of lipid lowering? What is the clinical significance of inflammatory and immunologic changes that persist after virologic suppression and how should they be managed? Will novel markers of CHD risk (eg, biomarkers or imaging studies) enhance risk prediction and stratification for HIV-infected patients? Should HIV infection itself be considered a CHD risk factor? Targeting HIV and CHD in a coordinated manner has the potential to significantly impact the long-term clinical care of HIV-infected patients and the development of public health strategies for cardiovascular prevention in this at-risk population.
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